In:
Hepatology Research, Wiley, Vol. 43, No. 10 ( 2013-10), p. 1005-1012
Abstract:
Although perihepatic lymph node enlargement ( PLNE ) is reportedly associated with the negative outcome of interferon therapy for chronic hepatitis C , there were limitations in that the results were obtained in patients with various genotypes, viral loads and treatment regimens. We aimed to precisely clarify the significance of PLNE in interferon therapy for chronic hepatitis C . Methods Between D ecember 2004 and J une 2005, 112 patients with hepatitis C virus ( HCV ) genotype 1 and HCV RNA of more than 100 KIU / mL were enrolled, who underwent pegylated interferon‐α plus ribavirin therapy thereafter. PLNE was defined as a perihepatic lymph node of more than 1 cm in the longest axis by ultrasonography. Results The sustained virological response ( SVR ) rate was lower in patients with PLNE (4/22, 18.2%) than in those without (37/90, 41.1%; P = 0.045) and viral load decline was smaller in patients with PLNE than in those without ( P = 0.028). The proportion of PLNE positive patients was the smallest in the SVR group ( P = 0.033) among the patient groups divided by the treatment outcome. PLNE was retained as a negative predictor for SVR by multivariate logistic regression analysis ( P = 0.012). Furthermore, PLNE was not significantly associated with the mutations at HCV core protein and at interferon sensitivity‐determining region, or interleukin ‐28B polymorphism in 45 patients with HCV genotype 1, enrolled between D ecember 2011 and M arch 2012. Conclusion PLNE is a negative predictor for SVR in patients with HCV genotype 1 and HCV RNA of more than 100 KIU / mL treated with pegylated interferon‐α plus ribavirin, independent of other known predictors for SVR .
Type of Medium:
Online Resource
ISSN:
1386-6346
,
1872-034X
DOI:
10.1111/hepr.2013.43.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
2006439-1
Permalink